Oculis Holding AG (NASDAQ:OCS) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Oculis Holding AG (NASDAQ:OCS) have received a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating and eight have issued a buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $41.50.

OCS has been the subject of a number of recent research reports. Wall Street Zen raised shares of Oculis from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. JPMorgan Chase & Co. assumed coverage on shares of Oculis in a report on Friday, December 19th. They issued an “overweight” rating and a $38.00 target price for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $36.00 price target on shares of Oculis in a report on Tuesday, November 11th. Lifesci Capital started coverage on shares of Oculis in a research report on Wednesday, December 3rd. They issued an “outperform” rating and a $55.00 price target for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Oculis in a research note on Thursday, January 22nd.

Oculis Stock Down 6.3%

OCS stock opened at $26.37 on Thursday. The business’s 50-day moving average is $22.44 and its two-hundred day moving average is $19.93. The company has a market cap of $1.38 billion, a price-to-earnings ratio of -10.46 and a beta of 0.28. Oculis has a fifty-two week low of $14.00 and a fifty-two week high of $29.36. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.47 and a current ratio of 4.47.

Oculis (NASDAQ:OCS) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.10. The firm had revenue of $0.31 million during the quarter, compared to analyst estimates of $0.23 million. Oculis had a negative net margin of 12,915.42% and a negative return on equity of 80.82%. As a group, analysts forecast that Oculis will post -2.09 earnings per share for the current year.

Hedge Funds Weigh In On Oculis

Hedge funds have recently made changes to their positions in the business. Gildi lifeyrissjodur purchased a new stake in shares of Oculis during the fourth quarter worth about $50,250,000. Aberdeen Group plc grew its holdings in Oculis by 39.4% during the 4th quarter. Aberdeen Group plc now owns 1,746,946 shares of the company’s stock valued at $34,887,000 after buying an additional 493,827 shares in the last quarter. Syquant Capital Sas bought a new stake in shares of Oculis during the fourth quarter valued at approximately $3,849,000. Compagnie Lombard Odier SCmA lifted its holdings in shares of Oculis by 10.6% in the fourth quarter. Compagnie Lombard Odier SCmA now owns 107,300 shares of the company’s stock worth $2,143,000 after buying an additional 10,300 shares in the last quarter. Finally, Woodline Partners LP boosted its position in shares of Oculis by 65.8% during the third quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock worth $1,474,000 after acquiring an additional 33,265 shares during the last quarter. Institutional investors own 22.30% of the company’s stock.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.